Inflammatory Process as a Determinant Factor for the Degeneration of Substantia Nigra Dopaminergic Neurons: Possible Relevance to the Etiology of Parkinsons Disease
Journal:
Current Medicinal Chemistry - Central Nervous System Agents
Volume:
4
Page:
223-233
Author(s):
M. Tomas-Camardiel, A.J. Herrera, J.L. Venero, J.Cano and A. Machado
The Hydrogen Peroxide and its Importance in Alzheimers and Parkinsons Disease
Journal:
Current Medicinal Chemistry - Central Nervous System Agents
Volume:
4
Page:
279-285
Author(s):
M. Jimenez Del Rio and C. Velez-Pardo
Genotyping as a Tool to Predict Adverse Drug Reactions
Journal:
Current Topics in Medicinal Chemistry
Volume:
4
Page:
1409-1419
Author(s):
Cuneyt Guzey and Olav Spigset
Pharmacological Aspects of (-)-Deprenyl
Journal:
Current Medicinal Chemistry
Volume:
11
Page:
2017-2031
Author(s):
K. Magyar, M. Palfi, T. Tabi, H. Kalasz, B. Szende and E. Szoko
Clinical Applications of MAO-Inhibitors
Journal:
Current Medicinal Chemistry
Volume:
11
Page:
2033-2043
Author(s):
P. Riederer, L. Lachenmayer and G. Laux
Neuroprotective Strategies for Parkinsons Disease
Journal:
Current Neuropharmacology
Volume:
2
Page:
309-322
Author(s):
Ippolita Cantuti-Castelvetri and David G. Standaert
Possible Neuroprotective Strategies for Huntingtons Disease
Journal:
Current Neuropharmacology
Volume:
2
Page:
331-342
Author(s):
James G. Greene
The Use of Antiparkinsonian Agents in the Management of Drug-Induced Extrapyramidal Symptoms
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
2239-2248
Author(s):
K. Burgyone, K. Aduri, J. Ananth and S. Parameswaran
Oligomers on the Brain: the Emerging Role of Soluble Protein Aggregates in Neurodegeneration.
Journal:
Protein & Peptide Letters
Volume:
11
Page:
213-228
Author(s):
Dominic M. Walsh and Dennis J. Selkoe
Impact of HLA Haplotype on the Response to Antipsychotic Treatment of Schizophrenia
Journal:
Current Pharmacogenomics
Volume:
2
Page:
149-155
Author(s):
L. Lahdelma and S. Koskimies